RNAC compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

RNACCartesian Therapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

RNACCartesian Therapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only RNAC 8

BIIBBiogen MA, Inc., or Biogensupplier

—National Institutes of Healthunlistedsupplier

—Genovis AB (publ.)unlistedsupplier

—NCIunlistedsupplier

4 more · RNAC chain ›

Shared 0

No shared counterparties.

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

25 more · LLY chain ›

RNACCartesian Therapeutics, Inc.

7.57▲+11.68%· post 7.57

Mkt cap$229.7MRevenue$78,000Q1 FY26Revenue$3MFY25

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

ClosedNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 6 '26

RNACCartesian Therapeutics, Inc.

LLYELI Lilly & Co

7.57▲+11.68%post 7.57

Price

1,360.90▼−0.28%post 1,358.90

$229.7M

Mkt cap

$1.2T

Q1 FY26$78,000

Revenue

$24.4BQ3 FY26

FY25$3M

Revenue

$65.2BFY25

RNAC7.57▲+11.68%vsLLY1,360.90▼−0.28%ClosedNov 6 '26